Mirxes receives FDA’s Breakthrough Device Designation for GASTROClear to advance blood-based cancer early detection
NEWSROOM Stay current with MiRXES Newsroom > Media Releases Mirxes receives FDA’s Breakthrough Device Designation for GASTROClearTM to advance blood-based cancer early detection SINGAPORE, 10 August 2023 – Mirxes Corporation USA, the wholly owned subsidiary of Mirxes Pte Ltd, a Singapore-headquartered RNA technology company that is making diagnostic solutions for the early detection of diseases …